Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents: A new generation of therapeutics

被引：32

作者：

Hursey, M ^{[1
]}

Newton, DL ^{[1
]}

Hansen, HJ ^{[1
]}

Ruby, D ^{[1
]}

Goldenberg, DM ^{[1
]}

Rybak, SM ^{[1
]}

机构：

[1] NCI, Div Canc Treatment & Diag, Dev Therapeut Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA

来源：

LEUKEMIA & LYMPHOMA | 2002年 / 43卷 / 05期

关键词：

antibody; ribonuclease; cancer; immunotoxin; apoptosis; CD22;

D O I：

10.1080/10428190290021380

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Targeting CD22 on human B-cells with a monoclonal antibody conjugated to a cytotoxic RNAse causes potent and specific killing of the lymphoma cells in vitro. This translates to anti-tumor effects in human lymphoma models in SCID mice. RNA damage caused by RNAses could be an important alternative to standard DNA-damaging chemotherapeutics. A second generation construct with an improved recombinant cytotoxic RNAse is described. Targeted RNAses may overcome problems of toxicity and immunogenicity associated with plant or bacterial toxin-containing immunoconjugates.

引用

页码：953 / 959

页数：7

共 49 条

[41]

Rybak S.M., 1993, DRUG DELIV, V1, P3

[42] Natural and engineered cytotoxic ribonucleases: Therapeutic potential [J].

Rybak, SM ;

Newton, DL .

EXPERIMENTAL CELL RESEARCH, 1999, 253 (02) :325-335

[43]

RYBAK SM, 1991, J BIOL CHEM, V266, P21202

[44] Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with Onconase, an antitumor ribonuclease [J].

Rybak, SM ;

Pearson, JW ;

Fogler, WE ;

Volker, K ;

Spence, SE ;

Newton, DL ;

Mikulski, SM ;

Ardelt, W ;

Riggs, CW ;

Kung, HF ;

Longo, DL .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (11) :747-753

[45] From housekeeper to microsurgeon: The diagnostic and therapeutic potential of ribonucleases [J].

Schein, CH .

NATURE BIOTECHNOLOGY, 1997, 15 (06) :529-536

[46]

Steineck G, 1993, Eur J Cancer Prev, V2, P293, DOI 10.1097/00008469-199307000-00002

[47]

VanHorssen PJ, 1996, INT J CANCER, V68, P378, DOI 10.1002/(SICI)1097-0215(19961104)68:3<378::AID-IJC17>3.0.CO

[48]

2-4

[49]

VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17

← 1 2 3 4 5 →